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Abstract  
Objective: To assess the feasibility of using D-Mannose, a natural food supplement, in 
patients with multiple sclerosis (MS) reporting recurrent urinary tract infections (UTIs) as a 
preventative.  
Methods: A single-centre, open-label, feasibility study enrolled patients with MS, using and 
not using urinary catheters, experiencing recurrent UTIs (≥3/year or ≥2/6 months). 
Participants were given D-mannose powder 1.5 grams twice daily for 16-weeks and were 
instructed to monitor suspected UTIs at home using urine dipsticks.  Diaries were used to 
record compliance, number of prescriptions of antibiotics received for UTIs, results of urine 
dipsticks and cultures. 
Results: Overall, 22 patients with MS, median age 50 years (46-59) were enrolled: 10 were 
not using catheters and 12 were using catheters. The compliance rates for using D-Mannose 
and dipsticks for testing suspected UTIs were 100% and 90.2% respectively. Sixty-one 
episodes of suspected UTIs were recorded, 19/61 (31.1%) were confirmed UTIs and 29/61 
(47.5%) prescriptions of antibiotics were made. The number of monthly proven UTIs 
decreased both in catheter users and non-users (p<0.01). No adverse effects were reported.   
Conclusion: Using D-mannose in patients with MS experiencing recurrent UTIs and self-
monitoring for infections is feasible and safe. Further studies are required to establish 
efficacy. CinicalTrials.gov (identifier NCT02490046). 
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Introduction 
Urinary tract infections (UTIs) commonly occur in patients with multiple sclerosis (MS) 
reporting lower urinary tract (LUT) dysfunction and are reported in 30% (ranging from 13% 
to 80%) of patients.1–3 Factors that predispose to UTIs have been poorly investigated in 
patients with MS, though postulated risk factors are incomplete bladder emptying, the use of 
a catheter, either intermittently or indwelling, and female gender.4 Infections occur more 
often in the MS population compared to the general population.5 and is one of the top three 
non-neurological causes for hospitalization, with a reported rate of 30-50% of all inpatient 
admissions.5,6 Recurrent UTIs are associated with significantly raised morbidity and mortality 
rates, triggering of relapses and have a detrimental impact on quality of life.7 Despite this, 
only a few options are available for preventing recurrent UTIs, antibiotic prophylaxis being 
the most common despite the lack of studies in MS.8,9 The use of oral antimicrobial 
prophylaxis for preventing UTIs in neurological patients with LUT dysfunction was not 
supported in a meta-analysis by Morton et al.10 and is currently not recommended as a routine 
by NICE (National Institute for Health and Care Excellence).11 Moreover, there are several 
disadvantages to using antibiotics over long periods including adverse reactions, increasing 
risk for bacterial resistance and costs.10 Therefore, alternative prophylactic agents have been 
explored. Studies evaluating cranberry extracts have reported conflicting results12,13 with one 
specifically looking at patients with MS (n=171)14 not showing any significant reduction in 
UTI rates. 
D-mannose is a monosaccharide isomer of glucose naturally found in the body and plays a 
role in human metabolism through the glycosylation of proteins. There is evidence to suggest 
that D-mannose inhibits bacterial adherence to urothelial cells.15 In vitro experiments have 
shown D-mannose binding to FimH adhesion located at the tip of type 1 fimbria of enteric 
bacteria.15 During bacterial colonization, FimH binds to carbohydrate-containing 
glycoprotein receptors on the epithelium of the urinary tract.16 D-mannose shares similarity in 
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structure to these urothelial glycoprotein receptors and therefore acts by competitively 
inhibiting bacterial adherence.  In vivo experimental studies in rat UTI models have shown 
that D-mannose can significantly reduce bacteriuria by a factor of 10 on the first and third 
days after D-Mannose inoculation, and by a factor >100 on days 5 and 7.17 A randomised 
controlled study that compared D-mannose, nitrofurantoin and no treatment in a group of 98 
women with recurrent UTIs demonstrated that D-mannose powder significantly reduced the 
risk of recurrent UTIs by 45%, comparable to the effects of prophylactic nitrofurantoin.18  
Moreover, side effects were significantly lower in D-mannose users compared to the 
nitrofurantoin group. More recently, a pilot study conducted in women without neurological 
disease demonstrated safety and efficacy of D-mannose compared to 
trimethoprim/sulfamethoxazole prophylaxis.19 Therefore, D-Mannose seems to be a viable 
option for the prevention of UTIs in a susceptible population. The objective of the study was 
to assess the feasibility of using D-Mannose in patients with MS reporting recurrent UTIs in 
preventing UTIs.   
 
Materials and methods 
Participants 
This prospective single-site open-label feasibility study enrolled patients with MS with LUT 
symptoms (ie. urinary urgency, frequency, urinary incontinence, incomplete bladder 
emptying) and reporting recurrent UTIs between February 2015 and August 2015 after 
obtaining written informed consent. Two groups of patients were considered: those who were 
not using urinary catheters and those who were using catheters. The inclusion criteria 
included:  clinically stable MS (relapsing or progressive) for at least three months, a history 
of recurrent UTIs (defined as having  2 proven UTIs in the preceding six months or 3 
proven UTIs in the preceding one year20 and age between 18 and 65 years. Exclusion criteria 
included pregnancy or patients planning to become pregnant during the study period, females 
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of childbearing potential with no effective contraception, patients with history of congenital 
urinary tract anomalies, interstitial cystitis, diabetes mellitus, current UTI or vaginal infection 
and any known allergies to D-mannose. Data including demographic characteristics, past 
medical history, vital signs, weight, physical examination, concomitant medications, 
symptoms of a UTI and standardised validated questionnaires to assess LUT symptoms 
(International Consultation on Incontinence Questionnaire- Overactive Bladder ICIQ-OAB,21 
Short-Form- Qualiveen SF-Qualiveen22  and EuroQoL five-dimensional 5-level version 
EQ5D-5L23) were collected at baseline and week 16.   
 
Protocol 
Participants were asked to take D-Mannose powder (Nature supplies, D-Mannose Ltd, Co 
Durham, UK) 1.5 grams twice daily, added to any beverage, for 16 weeks. Patients were not 
on any other prophylactic measures for preventing recurrent UTIs during the course of the 
study.  Patients maintained a diary to record usage of D-Mannose and any side effects. 
Compliance was assessed through weekly returns of the usage diary, phone calls at weeks 1 
and 8 of the treatment, and by weighing and counting containers at week 16. 
Participants were instructed to self-monitor suspected UTIs.  At the initial study visit they 
were educated about the symptoms and signs of UTIs including the presence of cloudy 
malodorous urine, haematuria, fever, feeling unwell, painful micturition, recent worsening of 
urgency/frequency/incontinence, suprapubic/flank pain, loin or abdominal discomfort, 
leakage between intermittent self-catheterization, catheter blockage, reduced appetite, and 
otherwise unexplained deterioration of pre-existing neurological condition or mobility and/or 
increasing spasticity 3. They were taught to use combined rapid urinalysis reagent strips 
(urine dipsticks) (Nature supplies, D-Mannose Ltd, Co Durham, UK) and read the results for 
leukocyte esterase and nitrites. General practitioners (GPs) were informed about the study 
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and were asked to evaluate participants with abnormal urine dipsticks (positive leukocytes 
and/or nitrites) for suspected UTIs including sending a sample to the lab for culture, and 
commence antibiotics, according to standard clinical practice.24 Participants maintained a 
UTI diary where the date of suspected UTIs, symptoms, results of urine dipsticks, results of 
culture and the name of antibiotics prescribed and the duration of treatment were recorded.  
Patients were asked to continue D-Mannose if they developed a UTI.  
 
Endpoints 
The primary endpoint was the D-mannose compliance over the 16-week course recorded on 
the compliance diary and expressed as a percentage. A weekly compliance rate of 100% 
signifies that the patient took D-Mannose twice a day for seven days. An overall compliance 
rate to D-Mannose was calculated based on the weekly compliance rates of each patient.  
Additional endpoints assessed the number of episodes of suspected UTIs, number of proven 
UTIs, the number of antibiotic prescriptions, results of urine dipstick test and accuracy of the 
test, urine culture results, safety of D-Mannose and the wish to continue D-Mannose at the 
end of the study. 
 
Statistical analysis 
Reported values were expressed as mean and ranges, median and interquartile range or as 
frequency and their corresponding percentages. Student’s t test and Wilcoxon’s sign rank test 
were used to compare variables, as appropriate. A P-value of <0.05 was considered 
significant. All analyses were performed using GraphPad prism version 5.0a (GraphPad 
Software, 2007 La Jolla, CA, USA). 
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The study was approved by local ethic approval (NRES Committee London-City Road & 
Hampstead, REC number 14/LO/2262) and registered with CinicalTrials.gov (identifier 
NCT02490046). 
 
Results 
Overall, 25 patients were screened and 22 patients (18 female, 4 men), median age 50 years 
(46.2-59) were enrolled in the study (3 patients excluded because two of them were planning 
pregnancy and one was recently diagnosed with diabetes). Participants were split into two 
groups: group 1 included patients with MS who were not using catheters (n=10) and group 2 
those who were using catheters (n=12; 9 using intermittent-self catheterizations and 3 
suprapubic catheters). The baseline characteristics are shown in table 1. One patient was lost 
to follow-up in group 1 and two early withdrawals occurred in group 2 (one patient 
experienced an MS relapse immediately after inclusion and before starting D-Mannose, one 
patient known to have epilepsy required hospitalization for seizures).  
In group 1 (n=10), the mean compliance rate was 99.7% (range 97.8-100; median 100% (IQR 
99.7-100). Seven patients had a compliance rate of 100%. The most common reason cited for 
not taking D Mannose was a failure to remember (n= 2) and generally feeling unwell (n=1). 
One patient mistakenly understood that D mannose should be stopped if a UTI occurred and 
was lost to follow up at week 11. No significant changes were observed in SF-Qualiveen, 
ICIQ-OAB, EQ5-5DL, EDSS scores or weight over the study period. 
In group 2 (n=11), the mean compliance rate was 99.4% (range 93.7-100; median 100% (IQR 
100-100). Nine patients had a compliance rate of 100%. The reason cited for not taking D 
Mannose was failure to remember (n=1), feeling sleepy (n=1), feeling sick (n=1) and seizure 
recurrence in an epileptic patient known to have frequent seizures (n=1). No adverse 
reactions to D-Mannose were reported.  No significant changes were observed in SF-
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Qualiveen, ICIQ-OAB, EQ5-5DL, EDSS scores or weight over the study period.   
Overall, 61 episodes of possible UTIs were recorded based on symptoms and signs.  In 55/61 
(90.2%), patients used urine dipsticks at home and recorded the results in the UTI diary.  
There were no recorded difficulties in using dipsticks, however in 6/61 (8.8%) episodes 
patients did not feel confident in their ability to interpret the results of dipsticks and therefore 
visited their GP for advice.  In 80% of episodes when the dipstick test was negative, patients 
felt confident about not having an infection and symptoms resolved without further 
investigations or treatments.  Eight patients (4 in each group) remained free of UTIs during 
the study period.    
Nineteen out of the 61 episodes (31.1%) were confirmed UTIs by culture. The median total 
number of symptomatic UTIs proven by urine culture was lower in group 1 (0.5 (0-1)) 
compared to group 2 (1 (0-2)) (table 2).  The number of monthly proven UTIs significantly 
decreased in both groups (p<0.01), by 75% in group 1 (0.5 to 0.12) and by 63% in group 2 
(0.67 to 0.25).  
A total of 29 prescriptions for antibiotics were made between these 61 episodes of suspected 
UTIs (47.5%). Antibiotics were prescribed without bacteriological evidence of UTIs in 10/61 
(16.4%) episodes. The median number of prescriptions was 1 (0-2.2) in group 1 and 2 (0-3) 
in group 2 (table 2). Table 3 shows the accuracy of the dipstick test for the diagnosis of 
culture-proven UTIs. In patients not using a catheter, the specificity and positive predictive 
value of a test being positive both for leukocytes and nitrites was high (100%) compared to 
patients using a catheter (58% and 54% respectively). In patients using a catheter, a test being 
negative for both leukocytes and nitrites had a specificity of 83%. 
At the end of the study, eight patients (80%) in group 1 and ten patients (90.9%) in group 2 
expressed a desire to continue taking D-Mannose. 
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Discussion 
In this study, we report that it is feasible for patients with MS experiencing recurrent UTIs to 
use D-Mannose, and that this was very well tolerated without any safety concerns. Indeed, 
the compliance for using D-Mannose was high (99.7% in group 1 and 99.4% in group 2). 
Moreover, the number of proven UTIs was reduced and the number of prescriptions of 
antibiotics was low.  Notably, most patients in our study population were females and had a 
high EDSS score; these are two factors that have been reported to increase the likelihood of 
UTIs in MS.3 Awareness about D-mannose is growing and only recently has it become 
available in the United Kingdom over the Internet. Randomized controlled trials suggested a 
benefit of using D-mannose in non-neurological women experiencing recurrent UTIs.18,19  
However, no clinical trials have been undertaken to test feasibility of using D-mannose 
amongst neurological patients.3,25 D-mannose is safe product, classed as a food supplement, 
with no significant safety signals identified in open label studies, with only diarrhoea rarely 
reported.18,19 The results of our study were in line with these reports.  
Our preliminary results seem to suggest a significant reduction in number of UTIs (by 75% in 
patients without catheter and by 63% in those without) though as the study was designed to 
evaluate only feasibility, no conclusions could be drawn about efficacy, however the results 
are encouraging and clearly, a randomized controlled study designed to evaluate efficacy is 
required.  
The study additionally used a model of follow-up using home-based self-monitoring of UTIs 
based on patient education and urinalysis using dipsticks. Urine dipsticks test appear to be a 
rapid and cost-effective test to help test for the diagnosis of UTIs.  Testing for nitrites and 
leukocyte esterase has been shown to be useful to screen for an infection, associated with a 
high negative predictive value.26 We chose to incorporate home-based urinalysis in this study 
as urine dipsticks are often used already by patients with MS in our service. In patients not 
using catheters, the specificity and positive predictive value of a positive result for both 
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leukocyte esterase and nitrites were high. However, the relevance of a positive result for one 
of these tests is uncertain and indeed in both groups, urine cultures were most often negative. 
A review with the GP is still advisable, as relying only on the urine dipstick test results in 
such a situation may result in might result in higher rates of overtreatment.27 
In patients using catheters, the value of the dipstick tests is less clear, because of the high 
prevalence of abnormal findings and asymptomatic bacteriuria.20 In this group in particular, 
symptoms and signs would guide the decision-making process.3   
In an emerging health care system of shared decision making,28 the decision to use antibiotics 
for a UTI is based on a set of complex processes including need recognition, information 
search and evaluation processes governed by the relationship and interactions between the 
physician and the patient.29 Matching this patients in our study were first instructed to 
recognize symptoms and signs of UTIs.3 They were asked to go to their GP in case of 
positive dipsticks, severe symptoms or if they did not feel confident in reading the results of 
the dipsticks.  In 55 of the 61 episodes of suspected UTIs, the urine dipstick test was 
performed at home (90%), and in about 80% of the time when the dipstick test was negative, 
the patients felt confident to self-manage without seeking the advice of the GP and symptoms 
resolved without further investigations or treatments. These results suggest that it is indeed 
feasible for patients with MS to self-monitor UTIs at home after being educated about 
symptoms of UTIs and using urine dipsticks. This should be studied in a larger population of 
patients with MS however before being adopted in a care pathway.   
 
Conclusion 
Recurrent UTIs are a significant problem in patients with MS and current available options 
are limited. This study demonstrates the feasibility of using D-mannose in patients with MS 
experiencing recurrent UTIs and self-monitoring for infections, without any safety concerns.  
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The use of D-mannose seems to be associated with a reduction in the number of UTIs and 
further studies are required to establish efficacy. A self-monitoring of UTIs at home after 
being educated about symptoms of UTIs and using urine dipsticks is a feasible care pathway 
strategy to adopt in patients with MS without catheter use and needs to be assessed in a larger 
population. 
 
Abbreviations: 
UTI: urinary tract infection 
MS: multiple sclerosis 
LUT: lower urinary tract 
MS: multiple sclerosis 
GP: general practitioner 
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Table 1. Patients’ baseline characteristics 
Characteristics Group 1 
Without catheter 
(n= 10) 
Group 2 
With catheter 
(n= 12) 
Age, years 51 (48-59.5) 48.5 (41.7-58.7) 
Gender, n (male/female)  0/10 
 
4/8 
 
Time since MS diagnosis, years 14.5 (8.7-25.2) 15.5 (3.7-20.5) 
Type of MS 
- primary progressive 
- relapse remitting 
- secondary progressive 
 
2 
5 
3 
 
2 
7 
3 
EDSS score 6.2 (5.5-6.5) 6.2 (6-7) 
Lower urinary tract symptoms 
- storage symptoms 
- voiding symptoms 
- mixed  
 
7 
3 
0 
 
7 
3 
2 
Number of UTIs per month in the preceding 6 months 0.5 (0.4-0.7) 0.7 (0.5-1) 
Data are expressed in median, interquartile range (25th-75th percentile) 
MS: multiple sclerosis, EDSS: Expanded disability status scale, UTI: urinary tract infection 
 
Table 2.  Number of symptomatic UTIs and antibiotic prescriptions in pwMS during 16-weeks 
treatment with D-Mannose  
 
 Group 1 without catheter (n= 10)  Group 2 with catheter (n= 12) 
Number of symptomatic UTIs per month 0.1 (0-0.2) 0.2 (0-0.5) 
Number of antibiotic prescriptions 1 (0-2.2) 2 (0-3) 
Total duration of antibiotic therapy (days) 7 (5.5-7) 7 (7-10) 
Data are expressed in median, interquartile range (25th-75th percentile) 
UTI: urinary tract infection; PwMS: people with multiple sclerosis 
 
Table 3. Accuracy of urine dipstick tests when culture was performed (n= 37)   
 
 Group 1 PwMS without catheter (n=10) Group 2 PwMS with catheter (n=12) 
 Leukocytes (+) 
and nitrites (+) 
Leukocytes (+) 
or nitrites (+) 
Leukocytes (-) 
and nitrites (-) 
Leukocytes (+) 
and nitrites (+) 
Leukocytes (+) 
or nitrites (+) 
Leukocytes (-) 
and nitrites (-) 
Sensitivity 50% 50% NA* 60% 10% 30% 
Specificity 100% 0% NA* 58% 58% 83% 
Positive 
predictive 
value 
100% 29% NA* 54% 17% 60% 
Negative 
predictive 
value 
71% 0% NA* 64% 44% 59% 
*NA: not applicable-   urine culture was not sent when the dipstick was negative for both leukocytes (leukocyte esterase) and 
nitrites  
PwMS: people with multiple sclerosis 
 
